YL064 directly inhibits STAT3 activity to induce apoptosis of multiple myeloma cells.

YL064 directly inhibits STAT3 activity to induce apoptosis of multiple myeloma cells.
复制标题

YL064直接抑制STAT3活性诱导多发性骨髓瘤细胞凋亡

DOI:
10.1038/s41420-018-0108-8
复制
发表时间:
2018
影响因子:
7
通讯作者:
Wu Y
Wu Y
中科院分区:
医学2区
文献类型:
--
作者:
Wang Y;Wu L;Cai H;Lei H;Ma CM;Yang L;Xu H;Zhu Q;Yao Z;Wu Y

文献摘要

参考文献

被引文献

相似文献

信号转导子和转录激活子 3 (STAT3) 的异常激活在多发性骨髓瘤的增殖和存活中发挥着关键作用。 STAT3的失活被认为是治疗多发性骨髓瘤的一种有前途的策略。在这里,我们发现青藤碱衍生物YL064可以选择性地降低多发性骨髓瘤细胞系和原代多发性骨髓瘤细胞的细胞活力。此外,在基质细胞存在的情况下,YL064 还可诱导骨髓瘤细胞死亡。 Western blot 分析表明,YL064 抑制 STAT3 的组成型激活和 IL-6 诱导的激活,这通过 Tyr705 上 STAT3 磷酸化的降低反映出来。与此一致的是,YL064抑制STAT3的核转位以及STAT3靶基因(例如细胞周期蛋白D1和Mcl-1)的表达。使用生物素和 FITC 标记的 YL064,我们发现 YL064 可以从骨髓瘤细胞中下拉 STAT3 并与 STAT3 共定位,表明 YL064 直接靶向 STAT3。细胞热位移测定进一步证明了细胞中 YL064 与 STAT3 的结合。分子对接研究表明,YL064可能与STAT3的SH2结构域相互作用,从而抑制STAT3的二聚化。最后,YL064在体内抑制人骨髓瘤异种移植物的生长。综上所述,这项研究表明,YL064 可能是一种有前途的候选化合物,通过直接靶向 STAT3 来治疗多发性骨髓瘤。
Aberrant activation of signal transducer and activator of transcription 3 (STAT3) plays a critical role in the proliferation and survival of multiple myeloma. And inactivation of STAT3 is considered a promising strategy for the treatment of multiple myeloma. Here we show that the sinomenine derivative YL064 could selectively reduce the cell viability of multiple myeloma cell lines and primary multiple myeloma cells. Moreover, YL064 also induces cell death of myeloma cells in the presence of stromal cells. Western blot analysis showed that YL064 inhibited the constitutive activation and IL-6-induced activation of STAT3, reflected by the decreased phosphorylation of STAT3 on Tyr705. Consistent with this, YL064 inhibited the nuclear translocation of STAT3 and the expression of STAT3 target genes, such as cyclin D1 and Mcl-1. Using biotin- and FITC-labeled YL064, we found that YL064 could pull-down STAT3 from myeloma cells and colocalized with STAT3, suggesting that YL064 directly targets STAT3. Cellular thermal shift assay further demonstrated the engagement of YL064 to STAT3 in cells. Molecular docking studies indicated that YL064 may interact with STAT3 in its SH2 domain, thereby inhibiting the dimerization of STAT3. Finally, YL064 inhibited the growth of human myeloma xenograft in vivo. Taken together, this study demonstrated that YL064 may be a promising candidate compound for the treatment of multiple myeloma by directly targeting STAT3.
DOI: 10.1016/j.ejmech.2012.12.051
发表时间: 2013-04-01
影响因子: 6.7
作者:
Jin, Jie;Teng, Peng;Li, Jian-Xin
通讯作者: Li, Jian-Xin
DOI: 10.1111/j.1476-5381.2011.01449.x
发表时间: 2011-11-01
影响因子: 7.3
作者:
Kannaiyan, Radhamani;Hay, Hui Sin;Sethi, Gautam
通讯作者: Sethi, Gautam
DOI: 10.1002/jcc.21256
发表时间: 2009-12
影响因子: 3
作者:
Morris, Garrett M.;Huey, Ruth;Lindstrom, William;Sanner, Michel F.;Belew, Richard K.;Goodsell, David S.;Olson, Arthur J.
通讯作者: Olson, Arthur J.
DOI: 10.1080/10428194.2017.1319052
发表时间: 2017-12
影响因子: 2.6
作者:
Muz B;Kusdono HD;Azab F;de la Puente P;Federico C;Fiala M;Vij R;Salama NN;Azab AK
通讯作者: Azab AK
DOI: 10.1038/sj.leu.2402924
发表时间: 2003-06-01
期刊: LEUKEMIA
影响因子: 11.4
作者:
Nefedova, Y;Landowski, TH;Dalton, WS
通讯作者: Dalton, WS